Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study.
暂无分享,去创建一个
S. de Servi | L. De Luca | S. Leonardi | D. Formigli | B. Tuccillo | L. Gonzini | M. Gulizia | F. Bovenzi | D. Lucci | Z. Olivari | Ignazio Maria Smecca
[1] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[2] S. de Servi,et al. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study , 2015, European heart journal. Acute cardiovascular care.
[3] A. Jaffe,et al. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .
[4] A. Jaffe,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[5] A. Go,et al. Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction. , 2014, Journal of the American College of Cardiology.
[6] C. Cannon,et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial , 2014, European heart journal.
[7] Deepak L. Bhatt,et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial , 2013, The Lancet.
[8] A. Morguet,et al. Baseline clinical characteristics. , 2013 .
[9] W. Boden,et al. Refining the role of antiplatelet therapy in medically managed patients with acute coronary syndrome. , 2013, The American journal of cardiology.
[10] Deepak L. Bhatt,et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. , 2012, The New England journal of medicine.
[11] R. Califf,et al. Regional Patterns of Use of a Medical Management Strategy for Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Insights From the EARLY ACS Trial , 2012, Circulation. Cardiovascular quality and outcomes.
[12] Giuseppe Ambrosio,et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. , 2012, The New England journal of medicine.
[13] C. Fox,et al. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. , 2011, JACC. Cardiovascular interventions.
[14] T. Lauer,et al. Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .
[15] C. Cannon,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial , 2011, BMJ : British Medical Journal.
[16] K. Alexander,et al. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). , 2010, JACC. Cardiovascular interventions.
[17] L. Newby,et al. Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative. , 2009, American heart journal.
[18] J. Gore,et al. Influence of age on use of cardiac catheterization and associated outcomes in patients with non-ST-elevation acute coronary syndromes. , 2009, The American journal of cardiology.
[19] Sunil V. Rao,et al. Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score , 2009, Circulation.
[20] K. Eagle,et al. Delay to angiography and outcomes following presentation with high-risk, non-ST-elevation acute coronary syndromes: results from the Global Registry of Acute Coronary Events , 2008, Heart.
[21] M. Sabatine,et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. , 2008, JAMA.
[22] P. Armstrong,et al. Noninvasive, medical management for non-ST-elevation acute coronary syndromes. , 2008, American heart journal.
[23] P. Poole‐Wilson,et al. Interventional versus conservative treatment in acute non-ST elevation coronary syndrome: time course of patient management and disease events over one year in the RITA 3 trial , 2006, Heart.
[24] S. Yusuf,et al. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial , 2004, Circulation.
[25] Á. Avezum,et al. A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry , 2004 .
[26] A. Jaffe,et al. Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .